Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
2. 2-(3-hydroxypropoxy)calcitriol
3. 20-epi-1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3
4. 20-epi-ed-71
5. 20-epi-eldecalcitol
6. Ed 71
7. Ed-71
1. Edirol
2. Ed-71
3. 104121-92-8
4. 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
5. I2jp8ue90h
6. (1r,2r,3r,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
7. 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3
8. Ed 71
9. (5z,7e)-(1r,2r,3r)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
10. 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol
11. (1r,2r,3r,5z,7e,14beta,17alpha)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
12. 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 / 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol
13. Eldecalcitol [inn]
14. 2-(3-hydroxypropoxy)calcitriol
15. Eldecalcitol [inn:jan]
16. Unii-i2jp8ue90h
17. Hy-a0020
18. Edirol (tn)
19. Eldecalcitol (jan/inn)
20. Eldecalcitol [mi]
21. Eldecalcitol [jan]
22. Eldecalcitol [mart.]
23. Eldecalcitol [who-dd]
24. Gtpl2783
25. Schembl5457151
26. Chembl4297608
27. Chebi:73927
28. 2beta-(3-hydroxypropoxy)calcitriol
29. (1s,2s,3s,z)-5-((e)-2-((1r,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-2-(3-hydroxypropoxy)-4-methylenecyclohexane-1,3-diol; Eldecalcitol
30. Ex-a5554
31. Zinc3934328
32. Ct-081
33. Lmst03020477
34. Akos025312299
35. Cs-0363
36. Db05295
37. 9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1alpha,2beta,3beta,5z,7e)-
38. Ac-26354
39. D07578
40. 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)-cholecalciferol
41. (1r,2r,3r,5z,7e)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
42. (5z,7e)-2.beta.-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1.alpha.,3.beta.,25-triol
43. Ed9
| Molecular Weight | 490.7 g/mol |
|---|---|
| Molecular Formula | C30H50O5 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 10 |
| Exact Mass | 490.36582469 g/mol |
| Monoisotopic Mass | 490.36582469 g/mol |
| Topological Polar Surface Area | 90.2 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 784 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in osteoporosis.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Eldecalcitol [1a,25-DIHYDROXY-2-(3-hydroxypropoxy)vitamin D3] is an analog of 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3], bearing a hydroxypropoxy residue at the 2b position. Eldecalcitol is also effective in increasing bone mass and was able to enhance bone strength in rodents. It binds to the vitamin D receptor (VDR) with less affinity but binds to vitamin D-binding protein with higher affinity than 1,25(OH)2D, showing a long half-life in plasma.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Eldecalcitol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eldecalcitol, including repackagers and relabelers. The FDA regulates Eldecalcitol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eldecalcitol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eldecalcitol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eldecalcitol supplier is an individual or a company that provides Eldecalcitol active pharmaceutical ingredient (API) or Eldecalcitol finished formulations upon request. The Eldecalcitol suppliers may include Eldecalcitol API manufacturers, exporters, distributors and traders.
click here to find a list of Eldecalcitol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Eldecalcitol Drug Master File in Japan (Eldecalcitol JDMF) empowers Eldecalcitol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Eldecalcitol JDMF during the approval evaluation for pharmaceutical products. At the time of Eldecalcitol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Eldecalcitol suppliers with JDMF on PharmaCompass.
Eldecalcitol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eldecalcitol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eldecalcitol GMP manufacturer or Eldecalcitol GMP API supplier for your needs.
A Eldecalcitol CoA (Certificate of Analysis) is a formal document that attests to Eldecalcitol's compliance with Eldecalcitol specifications and serves as a tool for batch-level quality control.
Eldecalcitol CoA mostly includes findings from lab analyses of a specific batch. For each Eldecalcitol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eldecalcitol may be tested according to a variety of international standards, such as European Pharmacopoeia (Eldecalcitol EP), Eldecalcitol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eldecalcitol USP).
LOOKING FOR A SUPPLIER?
